armesocarb (MLR-1019) / Melior, Adhera Therap - LARVOL DELTA

Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders (GlobeNewswire) - "Adhera Therapeutics, Inc...is pleased to announce that a new Canadian patent has been issued for MLR-1019 (armesocarb)....Melior has received a Notice of Allowance from the Canadian Intellectual Property Office for the patent, titled, 'Methods of Treating Dyskinesia and Related Disorders.'"

Patent • CNS Disorders • Parkinson's Disease

Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease (GlobeNewswire) - "Adhera Therapeutics, Inc...today announces that manufacturing has commenced of MLR-1019 (armesocarb) for use in the Company’s planned Phase 2a clinical trial as a new therapeutic for Parkinson’s disease (PD). Adhera is also pleased to inform shareholders that a new patent has been issued covering MLR-1019 in Korea."

New P2a trial • Patent • CNS Disorders • Parkinson's Disease

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs (GlobeNewswire) - "Adhera Therapeutics, Inc...today provides shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-1023 (tolimidone)....Adhera intends to initiate a Phase 2a clinical trial in an Eastern European jurisdiction where mesocarb still has marketing registration. The Company will undertake a parallel process in the U.S. with Investigational New Drug (IND)-enabling studies. Adhera believes that the comprehensive historical data in combination with new data from clinical trials in Europe will facilitate an accelerated development pathway in the U.S."

New P2a trial • Preclinical • CNS Disorders • Parkinson's Disease

Melior Pharmaceuticals Announces Execution of License Agreement for Armesocarb by Adhera Therapeutics (Businesswire) - "Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc. (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb)....Under the terms of the license Adhera is underwriting the cost of further MLR-1019 development. Further, upon attaining certain milestones, Adhera will have an option to fully acquire all intellectual property associated with MLR-1019."

Licensing / partnership • CNS Disorders • Parkinson's Disease

Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease (GlobeNewswire) - "Adhera Therapeutics...announce that the Company has signed a Letter of Intent (LOI) with Melior Pharmaceuticals II, LLC ('Melior Pharma 2'), pursuant to which Adhera will acquire MLR-1019 (armesocarb) from Melior Pharma 2. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD."

Licensing / partnership • CNS Disorders • Parkinson's Disease

Norbornene-Functionalized Plant Oils for Biobased Thermoset Films and Binders of Silicon-Graphite Composite Electrodes. (PubMed, ACS Omega) - "We herein report the functionalization of plant oil with norbornene (NB) and subsequent polymerization to prepare biobased thermoset films and biobased binders for silicon/mesocarbon microbead (MCMB) composite electrodes for use in lithium-ion batteries. Cell performance investigation showed that the silicone/MCMB composite electrode bearing the NBD-cross-linked NB-functionalized plant oil binder exhibited a higher C-rate and cycle-life performance than that using a conventional poly(vinylidene fluoride) (PVDF) binder. Finally, the electrode based on the bioderived binder exhibited a high specific charge capacity of 620 mA h g at 0.5 C."

Journal

Solid-electrolyte interphase nucleation and growth on carbonaceous negative electrodes for Li-ion batteries visualized with in situ atomic force microscopy. (PubMed, Sci Rep) - "Using this approach, we observed SEI nucleation and growth on highly oriented pyrolytic graphite (HOPG), MesoCarbon MicroBeads (MCMB) graphite, and non-graphitizable amorphous carbon (hard carbon)...The comparative observations revealed that the electrode potentials for SEI formation differ depending on the nature of the electrode material, whereas the adhesion of SEI to the electrode surface clearly correlates with the surface roughness of the electrode. Finally, the same approach applied to a positive LiNiMnCoO electrode did not reveal any signature of cathodic SEI thus demonstrating fundamental differences in the stabilization mechanisms of the negative and positive electrodes in Li-ion batteries."

Journal

MLR1019 reduces dyskinesias and subthalamic neuron bursting in rat 6OHDA Parkinsons disease model (Neuroscience 2017) - "These results indicate that MLR-1019 could represent a new PD therapeutic that significantly reduces the side effects and enhances the antiparkinsonian activity of L-DOPA treatment, as well as reduces STN bursting in lesioned brain. Efforts are underway to initiate a clinical trial to test MLR-1019 in PD patients."

CNS Disorders • Parkinson's Disease